Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm to Participate at Jefferies Virtual Healthcare Conference
-- Fireside Chat Scheduled for Tuesday, June 2, 2020 , at 9:30 a.m. ET -- NEWTON, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will
View HTML
Toggle Summary Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to discuss detailed results
View HTML
Toggle Summary Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
NEWTON, Mass. , May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO®
View HTML
Toggle Summary Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
NEWTON, Mass. , May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19
View HTML
Toggle Summary Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
Fireside Chat Scheduled for Tuesday, May 19, 2020, at 8:35 a.m. ET NEWTON, Mass. , May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will participate in
View HTML
Toggle Summary Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 -- -- First Quarter 2020 XPOVIO Net Product Sales of $16.1 Million and Total Revenues
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , May 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of
View HTML
Toggle Summary Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass. , April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company,
View HTML
Toggle Summary Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
-- Conference Call Scheduled for Tuesday, May 5, 2020 , at 8:30 a.m. ET -- NEWTON, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020 .
View HTML
Toggle Summary Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
NEWTON, Mass. , April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19.
View HTML